Comparative Pharmacology
Head-to-head clinical analysis: ALPHATREX versus TREPROSTINIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHATREX versus TREPROSTINIL.
ALPHATREX vs TREPROSTINIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALPHATREX is a synthetic corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene transcription and suppression of inflammatory cytokines, immune responses, and edema.
Treprostinil is a synthetic prostacyclin analogue that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses vascular smooth muscle proliferation via activation of IP receptors and subsequent increase in cAMP levels.
1-2 mg/kg IV every 24 hours; maximum single dose 150 mg.
Continuous subcutaneous or intravenous infusion via infusion pump. Initial rate: 1.25 ng/kg/min; if not tolerated, reduce to 0.625 ng/kg/min. Titrate in increments of 1.25 ng/kg/min per week for first 4 weeks, then 2.5 ng/kg/min per week as tolerated. Typical maintenance dose: 25-40 ng/kg/min. Duration: continuous long-term.
None Documented
None Documented
Clinical Note
moderateTreprostinil + Benzydamine
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Benzydamine."
Clinical Note
moderateTreprostinil + Droxicam
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Droxicam."
Clinical Note
moderateTreprostinil + Loxoprofen
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Loxoprofen."
Clinical Note
moderateTreprostinil + Clonixin
Terminal elimination half-life is 12-18 hours in patients with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl <50 mL/min).
Terminal half-life is approximately 4 hours for intravenous administration; clinical context: requires continuous infusion due to short half-life.
Renal excretion of unchanged drug accounts for 40-60% of elimination; hepatic metabolism accounts for 30-40%, with metabolites excreted in bile and feces (10-20%).
Primarily hepatic metabolism via CYP2C8; renal excretion of unchanged drug is approximately 4% of the dose.
Category C
Category A/B
Prostacyclin Analog
Prostacyclin Analog
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Clonixin."